Order Article Reprints

Mussini C, Cozzi-Lepri A, Meschiari M, Franceschini E, Burastero G, Faltoni M, Franceschi G, Iadisernia V, Volpi S, Dessilani A, et al. Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study. Viruses. 2023; 15(2):294. https://doi.org/10.3390/v15020294

Mussini, Cristina, Alessandro Cozzi-Lepri, Marianna Meschiari, Erica Franceschini, Giulia Burastero, Matteo Faltoni, Giacomo Franceschi, Vittorio Iadisernia, Sara Volpi, Andrea Dessilani, and et al. 2023. "Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study" Viruses 15, no. 2: 294. https://doi.org/10.3390/v15020294

Mussini, C., Cozzi-Lepri, A., Meschiari, M., Franceschini, E., Burastero, G., Faltoni, M., Franceschi, G., Iadisernia, V., Volpi, S., Dessilani, A., Gozzi, L., Conti, J., Del Monte, M., Milic, J., Borghi, V., Tonelli, R., Brugioni, L., Romagnoli, E., Pietrangelo, A., ... Guaraldi, G. (2023). Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study. Viruses, 15(2), 294. https://doi.org/10.3390/v15020294